{"id":48765,"date":"2025-11-21T22:00:19","date_gmt":"2025-11-21T14:00:19","guid":{"rendered":"https:\/\/flcube.com\/?p=48765"},"modified":"2025-11-21T22:00:20","modified_gmt":"2025-11-21T14:00:20","slug":"abbott-to-acquire-exact-sciences-for-21b-entering-cancer-diagnostics-leadership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48765","title":{"rendered":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership"},"content":{"rendered":"\n<p><strong>Abbott Laboratories<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/ABT:NYSE\">NYSE: ABT<\/a>) and <strong>Exact Sciences Corp.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/EXAS:NASDAQ\">NASDAQ: EXAS<\/a>) announced a <strong>definitive agreement<\/strong> under which Abbott will acquire Exact Sciences for <strong>$105 per share<\/strong>, representing a total equity value of <strong>approximately $21\u202fbillion<\/strong>, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-terms\">Transaction Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Abbott Laboratories (NYSE: ABT)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Exact Sciences Corp. (NASDAQ: EXAS)<\/td><\/tr><tr><td><strong>Offer Price<\/strong><\/td><td>$105 per common share (cash)<\/td><\/tr><tr><td><strong>Total Equity Value<\/strong><\/td><td>~USD\u202f21\u202fbillion<\/td><\/tr><tr><td><strong>Expected Closing<\/strong><\/td><td>H2\u202f2026 (subject to regulatory approvals)<\/td><\/tr><tr><td><strong>Strategic Rationale<\/strong><\/td><td>Enter and lead cancer diagnostics; accelerate innovation and access<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-exact-sciences-portfolio\">Exact Sciences Portfolio<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cologuard:<\/strong> Market\u2011leading <strong>noninvasive colorectal cancer screening<\/strong> test<\/li>\n\n\n\n<li><strong>Oncotype\u202fDX:<\/strong> Guides <strong>personalized treatment decisions<\/strong> in breast cancer<\/li>\n\n\n\n<li><strong>Oncodetect:<\/strong> Identifies <strong>molecular residual disease (MRD)<\/strong> to assess recurrence risk and guide follow\u2011up<\/li>\n\n\n\n<li><strong>Cancerguard:<\/strong> <strong>Multi\u2011cancer early detection<\/strong> blood test in development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-synergies\">Strategic Synergies<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Innovation Acceleration:<\/strong> Combine Abbott\u2019s global R&amp;D infrastructure with Exact Sciences\u2019 oncology expertise<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Leverage Abbott\u2019s <strong>130\u2011country distribution network<\/strong> to expand Cologuard and Oncotype\u202fDX reach<\/li>\n\n\n\n<li><strong>Revenue Diversification:<\/strong> Adds <strong>~$2.5\u202fbillion<\/strong> high\u2011growth diagnostics revenue to Abbott\u2019s base<\/li>\n\n\n\n<li><strong>Cost Synergies:<\/strong> Estimated <strong>$300\u2011400\u202fmillion<\/strong> annual run\u2011rate savings by 2027 through operational integration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Market Size (2024)<\/th><th>Growth CAGR<\/th><th>Abbott+Exact Share Post\u2011Close<\/th><\/tr><\/thead><tbody><tr><td><strong>Colorectal Cancer Screening<\/strong><\/td><td>$4.5\u202fbillion<\/td><td>12%<\/td><td><strong>~40%<\/strong> (Cologuard dominant)<\/td><\/tr><tr><td><strong>Breast Cancer Diagnostics<\/strong><\/td><td>$2.8\u202fbillion<\/td><td>8%<\/td><td><strong>~15%<\/strong> (Oncotype\u202fDX leader)<\/td><\/tr><tr><td><strong>MRD Testing<\/strong><\/td><td>$1.2\u202fbillion<\/td><td>35%<\/td><td><strong>~8%<\/strong> (Oncodetect early player)<\/td><\/tr><tr><td><strong>Multi\u2011Cancer Early Detection<\/strong><\/td><td>$0.3\u202fbillion<\/td><td>50%+<\/td><td><strong>Pioneering<\/strong> (Cancerguard)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Forecast:<\/strong> Exact Sciences\u2019 oncology portfolio projected to contribute <strong>$4.0\u20114.5\u202fbillion<\/strong> ** to Abbott\u2019s top line by 2030**<\/li>\n\n\n\n<li><strong>EPS Accretion:<\/strong> Expected to be <strong>accretive<\/strong> to Abbott\u2019s adjusted EPS in year two post\u2011closing<\/li>\n\n\n\n<li><strong>Financing:<\/strong> Abbott plans to fund the transaction through a combination of cash and debt; maintains investment\u2011grade<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the Abbott\u2011Exact Sciences transaction, expected synergies, and financial impact. Actual results may differ materially due to risks including regulatory approval delays, integration challenges, and competitive dynamics in the diagnostics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48766,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[503,2296,4470,870],"class_list":["post-48765","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abbott","tag-exact-sciences","tag-nasdaq-exas","tag-nyse-abt"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under which Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of approximately $21\u202fbillion, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48765\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership\" \/>\n<meta property=\"og:description\" content=\"Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under which Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of approximately $21\u202fbillion, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48765\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-21T14:00:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-21T14:00:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership\",\"datePublished\":\"2025-11-21T14:00:19+00:00\",\"dateModified\":\"2025-11-21T14:00:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765\"},\"wordCount\":332,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2105.webp\",\"keywords\":[\"Abbott\",\"Exact Sciences\",\"NASDAQ: EXAS\",\"NYSE: ABT\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48765#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48765\",\"name\":\"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2105.webp\",\"datePublished\":\"2025-11-21T14:00:19+00:00\",\"dateModified\":\"2025-11-21T14:00:20+00:00\",\"description\":\"Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under which Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of approximately $21\u202fbillion, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48765\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2105.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2105.webp\",\"width\":1080,\"height\":608,\"caption\":\"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48765#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership - Insight, China&#039;s Pharmaceutical Industry","description":"Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under which Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of approximately $21\u202fbillion, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48765","og_locale":"en_US","og_type":"article","og_title":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership","og_description":"Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under which Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of approximately $21\u202fbillion, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.","og_url":"https:\/\/flcube.com\/?p=48765","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-21T14:00:19+00:00","article_modified_time":"2025-11-21T14:00:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48765#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48765"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership","datePublished":"2025-11-21T14:00:19+00:00","dateModified":"2025-11-21T14:00:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48765"},"wordCount":332,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48765#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp","keywords":["Abbott","Exact Sciences","NASDAQ: EXAS","NYSE: ABT"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48765#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48765","url":"https:\/\/flcube.com\/?p=48765","name":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48765#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48765#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp","datePublished":"2025-11-21T14:00:19+00:00","dateModified":"2025-11-21T14:00:20+00:00","description":"Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under which Abbott will acquire Exact Sciences for $105 per share, representing a total equity value of approximately $21\u202fbillion, positioning Abbott as a leader in the fast\u2011growing cancer diagnostics segment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48765#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48765"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48765#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp","width":1080,"height":608,"caption":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48765#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Abbott to Acquire Exact Sciences for $21B, Entering Cancer Diagnostics Leadership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2105.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48765"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48765\/revisions"}],"predecessor-version":[{"id":48767,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48765\/revisions\/48767"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48766"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}